In Situ Hybridization (ISH)

In Situ Hybridization (ISH)

Global In Situ Hybridization (ISH) Market to Reach $1.5 Billion by 2030
The global market for In Situ Hybridization (ISH) estimated at US$908 Million in the year 2022, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 6.6% over the period 2022-2030. Fluorescence In Situ Hybridization (FISH), one of the segments analyzed in the report, is expected to record 6.4% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Chromogenic In Situ Hybridization (CISH) segment is estimated at 7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $377.5 Million, While China is Forecast to Grow at 8% CAGR
The In Situ Hybridization (ISH) market in the U.S. is estimated at US$377.5 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$107.4 Million by the year 2030 trailing a CAGR of 8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 38 Featured) -
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioGenex
  • Abnova Corporation
  • Bio-Techne Corporation
  • Biocare Medical LLC
  • Leica Biosystems Nussloch GmbH
  • Advanced Cell Diagnostics, Inc.
  • Empire Genomics LLC
  • Biodot, Inc.
  • IMRIS, Deerfield Imaging, Inc.
  • Creative Biolabs
  • Bio Sb
  • Guangzhou Ruibo Biotechnology Co., Ltd.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
In Situ Hybridization (ISH) - Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
Global Economic Update
In Situ Hybridization: A Prelude
Future Prospects Remain Favorable for Insitu Hybridization
Chromogenic ISH: Gaining Over FISH
FISH Technology Continues to Find Favor
How is FISH Better than Conventional Techniques?
Probe Types and Application
Fluorescent In Situ Hybridization Emerges as Cytological Tool of Choice for Plethora of Scientific Applications
Recent Market Activity
World Brands
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Cancer Drives the Demand for In-situ Hybridization
Diverse Applications of FISH Technology in Oncology
Growing Demand for Targeted Therapies in Cancer Treatment Presents Lucrative Opportunities
Growing Number of Genetic Disorders and Emphasis on Genetic Testing Bodes Well for the Growth of ISH Market
List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
Top Ten Genetic Diseases Worldwide
Rise in Prenatal Testing Drives Opportunities
FISH in Detection of Prenatal Genetic Abnormalities
In Situ Hybridization Advances Present Perfect Tools to Detect Genetic Anomalies
Uptrend in Companion Diagnostics Market Augurs Well
World Companion Diagnostics Market (in US$ Million) for the Years 2019, 2021, 2023 & 2025
Companion Diagnostics Lead the Way to Personalized Medicine
Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
State-Sponsored Molecular Research Initiatives Bode Well for Market Growth
Increasing Research on Application of ISH in infectious Disease Diagnostics to Drive Growth
Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %) Cause % Share
Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
FISH in Detection of Microbiological Pathogens
Growth in In-vitro Diagnostics (IVD) for Diagnosis of Chronic Diseases Promise Opportunities
High Demand for IVD Devices Promises Opportunities for FISH Probes: Global IVD Instruments Market (In US$ Billion) for the Years 2018, 2020, 2022, 2024 & 2027
Rising R&D Investments in the Biotech Sector Drives Gains
Emergence of Automated Diagnostic Kits
Novel Approach of Highly-Multiplexed FISH for In-Situ Genomics
Technology Advancements & Improvements Bolster Growth
Rise in Healthcare Expenditure to Drive Growth
World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
Ageing Demographics to Drive Demand
Elderly Healthcare Expenditure as a % of GDP
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Fluorescence In Situ Hybridization (FISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Fluorescence In Situ Hybridization (FISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Fluorescence In Situ Hybridization (FISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Chromogenic In Situ Hybridization (CISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Chromogenic In Situ Hybridization (CISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Chromogenic In Situ Hybridization (CISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Neuroscience by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Cytology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Cytology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Hospitals & Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Hospitals & Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 29: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 30: World 16-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 32: World Historic Review for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 33: World 16-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Automation Equipment Benefit the In-Situ Hybridization Market
TABLE 34: World In Situ Hybridization (ISH) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 35: World Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: World 16-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Canada 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Canada Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Canada 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
JAPAN
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Japan Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Japan 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Japan 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
CHINA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 65: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: China Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: China 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: China Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: China 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: China Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: China 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
EUROPE
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Europe Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Europe 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for In Situ Hybridization (ISH) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 86: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: France Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: France 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: France Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: France 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: France Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: France 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
GERMANY
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Germany Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Germany 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Germany Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Germany 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Germany Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Germany 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Italy 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Italy Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Italy 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Italy Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Italy 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
UNITED KINGDOM
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: UK Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: UK 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: UK Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: UK 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: UK Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: UK 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
SPAIN
TABLE 122: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Spain Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: Spain 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Spain Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Spain 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Spain Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Spain 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
RUSSIA
TABLE 131: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Russia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Russia 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Russia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Russia 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Russia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Russia 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of Europe 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of Europe 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of Europe 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
ASIA-PACIFIC
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 151: Asia-Pacific 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 154: Asia-Pacific 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 157: Asia-Pacific 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
AUSTRALIA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 161: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 162: Australia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 163: Australia 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 165: Australia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 166: Australia 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 168: Australia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 169: Australia 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
INDIA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 170: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 171: India Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 172: India 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 174: India Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 175: India 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 177: India Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 178: India 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 179: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 181: South Korea 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 184: South Korea 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 187: South Korea 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 190: Rest of Asia-Pacific 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 193: Rest of Asia-Pacific 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 196: Rest of Asia-Pacific 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
LATIN AMERICA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 197: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 199: Latin America 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 202: Latin America 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 205: Latin America 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for In Situ Hybridization (ISH) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 208: Latin America 16-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
ARGENTINA
TABLE 209: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 211: Argentina 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 214: Argentina 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 217: Argentina 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
BRAZIL
TABLE 218: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 220: Brazil 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 223: Brazil 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 226: Brazil 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
MEXICO
TABLE 227: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 229: Mexico 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 232: Mexico 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 235: Mexico 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 238: Rest of Latin America 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 241: Rest of Latin America 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 244: Rest of Latin America 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
MIDDLE EAST
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 245: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 247: Middle East 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 250: Middle East 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 253: Middle East 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for In Situ Hybridization (ISH) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 256: Middle East 16-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
IRAN
TABLE 257: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 258: Iran Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 259: Iran 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 261: Iran Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 262: Iran 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 264: Iran Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 265: Iran 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
ISRAEL
TABLE 266: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 267: Israel Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 268: Israel 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 270: Israel Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 271: Israel 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 273: Israel Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 274: Israel 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 277: Saudi Arabia 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 280: Saudi Arabia 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 283: Saudi Arabia 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 284: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 285: UAE Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 286: UAE 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 288: UAE Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 289: UAE 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 291: UAE Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 292: UAE 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 295: Rest of Middle East 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 298: Rest of Middle East 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 301: Rest of Middle East 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
AFRICA
In Situ Hybridization (ISH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 302: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 303: Africa Historic Review for In Situ Hybridization (ISH) by Technique - Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 304: Africa 16-Year Perspective for In Situ Hybridization (ISH) by Technique - Percentage Breakdown of Value Revenues for Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) for the Years 2014, 2024 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 306: Africa Historic Review for In Situ Hybridization (ISH) by Application - Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 307: Africa 16-Year Perspective for In Situ Hybridization (ISH) by Application - Percentage Breakdown of Value Revenues for Cancer Diagnostics, Immunology, Neuroscience, Cytology and Infectious Disease Diagnostics for the Years 2014, 2024 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 309: Africa Historic Review for In Situ Hybridization (ISH) by End-Use - Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 310: Africa 16-Year Perspective for In Situ Hybridization (ISH) by End-Use - Percentage Breakdown of Value Revenues for Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutions for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings